Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/skin-and-ocular-irritation-alternatives-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Alternative Test MethodsSkin and Ocular Irritation Alternative Test Method Patents
- Filings jumped from 1 in 2021 to 10 in 2024, a +900% rise over three years, right as non-animal test methods gained regulatory traction.
- One assignee holds 14 of the ranked families, while nine others hold single-digit counts — a leader-plus-long-tail structure, not a crowded field.
- Medicinal preparations (A61K) touch half of all records, but cosmetics, detergents and radiation-measurement classes each sit at only 20% — narrower claim territory to work with.
20
Published Records
+900%
Filing Growth 2021→2024
US
Leading Jurisdiction
11
Active Filers Ranked
Filing growth compares 2021 (1 records) with 2024 (10) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Overview
What this landscape covers
This review covers patent families matching reconstructed human epidermis, ocular irritation test and skin sensitization assay language paired with terms like barrier function control, prediction model and protocol harmonization — the vocabulary of non-animal alternatives to skin and eye irritation testing. The scope runs from 2015 through the 2026-07-31 cut-off.
Twenty patent families sit in scope, filed at United States, WIPO, European, Australian, Canadian and UK receiving offices. The United States is the dominant filing venue by a wide margin, which matters for anyone assessing freedom to operate in that jurisdiction first.
Filing activity and technology mix, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Skin and Ocular Irritation Alternatives covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Data
Filing trend and technology composition
Two views of the same 20-record dataset: how filing activity moved year over year, and which IPC subclasses the claims actually sit in.
From a single filing to a peak year
Filings were flat near zero through the late 2010s, then rose sharply: 2021 recorded 1 filing, 2024 recorded 10 — the peak year so far, a +900% increase across that span. Because publication trails filing by roughly 18 months, the 2025 and 2026 figures are still incomplete and should not be read as a slowdown.
Claims cluster in a few subclasses
A61K (medicinal preparations) appears in 50.0% of the 20 records in scope, the single most common subclass. C12Q (enzyme/DNA-based measuring and testing) and G01N (material analysis and testing) each cover 35.0% of records. A61H, A61Q, C11D and G01J each sit at 20.0%, and A61P at 15.0% — since records can carry multiple classes, these shares add to more than 100%.
Shares are the percentage of the 20 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Skin and Ocular Irritation Alternatives covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Skin and Ocular Irritation Alternatives with Eureka
This page is one run against one query. Ask Eureka your own question about skin and ocular irritation alternatives and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
A representative filing
Representative Filing
In chemico test for toxicity
LEBRUN LABS LLC
The disclosure relates to formulations and methods for the in chemico testing of toxins based on a discovery that measuring a reduction in enzyme activity can be used to predict in vivo toxicity, including for example skin corrosion, skin irritation, eye corrosion, eye irritation, lung toxicity, liver toxicity, nervous system toxicity, developmental toxicity and acute toxicity. Disclosed methods are rapid, easy to perform and shelf-stable approaches for identification of toxic chemicals and materials.Filed by the dataset's leading assignee; enzyme-activity readouts sit at the centre of its claim strategy.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Skin and Ocular Irritation Alternatives covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing decision
Read alongside the trend and technology charts, three patterns stand out for anyone deciding where to file or where to watch.
Growth
+900% (2021→2024)
filing growth, three-year span
A young field accelerating fast
Filing activity went from a single family in 2021 to ten in 2024, the peak year so far. That is a sharp acceleration for a field this small, and it lines up with tightening regulatory pressure on animal-based irritation testing in several jurisdictions.
2024 is the last year that can be read as complete.
Concentration
14 vs 1
leader vs tenth-ranked family count
One assignee, then a long tail
The leading assignee holds 14 of the ranked families; the fifth-placed and tenth-placed assignees each hold just 1. That gap says the field has a dominant filer rather than a broad competitive cluster, which changes how a freedom-to-operate search should be scoped.
11 companies make up the entire ranked list.
Geography
9 of 20 filings
United States receiving office
US-centred filing pattern
United States receiving-office filings outnumber WIPO, EPO, Australian, Canadian and UK filings combined among the routes tracked. A US-first clearance search will catch most of the exposure, but the PCT and EPO filings still need separate checking for regional strategy.
WIPO (PCT) is the second most-used route at 4 filings.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to skin and ocular irritation alternatives, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Skin and Ocular Irritation Alternatives covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the gaps sit
The ranked list is short — 11 companies in total — and dominated by one filer, with individual inventors and research institutes making up most of the rest.
Leader
14 families
ranked family count
A single dominant filer
One assignee holds 14 of the 20 ranked patent families, built around enzyme-activity and in chemico toxicity testing methods. Its claim scope around reduction-in-enzyme-activity readouts is the first thing to check before filing anything adjacent.
Its most recent filing is dated 2025-03-27.
Long tail
1 family
fifth and tenth-ranked assignees
Institutes and individual inventors
Below the leader, family counts drop quickly to single digits, with research institutes and universities holding isolated filings rather than sustained programmes. That pattern suggests opportunistic or academic filing rather than a coordinated competitive race.
Co-assignee pairs, such as institute-plus-inventor combinations, appear only a handful of times.
Momentum
-100% YoY
latest-year change, several assignees
Recent activity has gone quiet
Several tracked assignees, including the leader, show zero filings in the latest year with a -100% year-on-year change. Given the 18-month publication lag, this reads as incomplete data rather than a real pullback, but it means recent competitive signal is thin.
Treat 2025-2026 figures as provisional until later publications land.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| LEBRUN LABS LLC | 0 | -100% |
| LANKEM LTD | 0 | — |
| NGUYEN LINDA | 0 | — |
| LEBRUN STEWART | 0 | — |
| Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | 0 | -100% |
| Hadasit Medical Research Services & Development Ltd | 0 | -100% |
| ZINGKOU ELENI | 0 | — |
| UNIVERSTY OF PATRAS | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Skin and Ocular Irritation Alternatives covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this next
The dataset points to a narrow, fast-moving field with one dominant filer and several open branches. Two paths make sense depending on what you need to decide.
Run a freedom-to-operate check on enzyme-activity claims
Before filing anything involving in chemico toxicity prediction, check the leading assignee's claim scope directly — its enzyme-reduction readout approach covers a meaningful share of the field's core method claims.
Explore this in Eureka →Map the under-claimed branches to your own pipeline
Barrier function control, batch qualification and borderline classification models all show low filing density relative to the core testing-method claims. If your work touches any of these, a first-mover filing is still realistic.
Explore this in Eureka →Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Skin and Ocular Irritation Alternatives covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
This landscape tracks 20 patent families published between 2015 and the 2026-07-31 data cut-off, matching search terms around reconstructed human epidermis, ocular irritation testing and skin sensitization assays combined with terms like barrier function control and prediction model. That is a small, specialised field rather than a broad one. Because publication lags filing by roughly 18 months, the true count for 2025 and 2026 filings will rise as more applications publish.
The ranked list covers 11 companies, and it is heavily front-loaded: the leading assignee holds 14 of the 20 ranked families, built around in chemico toxicity testing using enzyme-activity readouts. The fifth-ranked and tenth-ranked assignees each hold just 1 family, meaning most of the remaining organisations are single-filing research institutes, universities or individual inventors rather than sustained corporate programmes.
Filings grew sharply, from 1 family in 2021 to 10 in 2024, a +900% increase over that three-year span and the field's peak year to date. Figures for 2025 and 2026 appear lower, but that reflects the normal 18-month lag between filing and publication rather than a genuine slowdown. Treat any recent-year dip in this dataset as incomplete data, not a trend reversal.
Half of the 20 records in scope carry an A61K (medicinal preparations) classification, the single most common category. Enzyme- and DNA-based measuring methods (C12Q) and material analysis and testing (G01N) each appear in 35.0% of records, while cosmetics use, detergents, physical therapy and radiation-measurement classes each sit around 20.0%. Since a single record can carry several IPC classes, these shares add up to more than 100% and should be read as overlapping claim footprints, not exclusive categories.
The technology composition shows several subclasses sitting at only 20% of records — radiation and light measurement, detergent and cleaning-compatibility testing, and physical therapy applications among them — compared with the 50% concentration in medicinal preparations. Combined with the fact that only one assignee holds a sustained filing programme, branches like batch qualification protocols and borderline classification modelling look under-claimed relative to the core testing-method space. A targeted prior-art search on those specific branches, rather than the field as a whole, is the practical next step.
Answers are grounded in the same dataset. Derived from a Patsnap search on Skin and Ocular Irritation Alternatives covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Skin and Ocular Irritation Alternatives in depth with Eureka
Go past this page: query the whole skin and ocular irritation alternatives corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.